SFI
ALNY icon

Susquehanna Fundamental Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56,585
Closed -$13.3M – 1064
2024
Q4 		$13.3M Buy
+56,585
New +$14.9M 0.19% 135
2024
Q2 		$13.8M Sell
56,585
-31,482
-36% -$4.97M 0.32% 93
2024
Q1 		$13.2M Buy
+88,067
New +$14.7M 0.61% 38
2022
Q1 		$2.31M Buy
14,180
+7,892
+126% +$1.2M 0.05% 524
2021
Q4 		$1.07M Hold
6,288
– – 0.03% 627
2021
Q3 		$1.19M Hold
6,288
– – 0.02% 795
2021
Q2 		$1.07M Sell
6,288
-17,733
-74% -$2.6M 0.02% 829
2021
Q1 		$3.39M Buy
+24,021
New +$3.61M 0.06% 462
2020
Q4 		– Sell
-7,596
Closed -$1.11M – 1481
2020
Q3 		$1.11M Buy
+7,596
New +$1.08M 0.03% 605

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's ALNY Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 56,585 shares — an estimated $13.3M sold.

Susquehanna Fundamental Investments first reported a position in ALNY in Q3 2020 and held it in 9 quarters. The position peaked at $13.8M in Q2 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Susquehanna Fundamental Investments reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 56,585 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $13.3M.
  • Susquehanna Fundamental Investments first reported a position in Alnylam Pharmaceuticals in Q3 2020 and held it in 9 quarters.
  • Susquehanna Fundamental Investments's Alnylam Pharmaceuticals position peaked at $13.8M in Q2 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.